Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,415.00
+64.00 (4.74%)
Mar 10, 2026, 3:30 PM KST

Xcell Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
23,36544,384----
Upgrade
Enterprise Value
28,51138,298----
Upgrade
Last Close Price
1351.003373.54----
Upgrade
PS Ratio
17.1522.95----
Upgrade
PB Ratio
14.404.87----
Upgrade
P/TBV Ratio
26.305.17----
Upgrade
EV/Sales Ratio
20.9319.80----
Upgrade
Debt / Equity Ratio
3.930.632.730.690.383.54
Upgrade
Net Debt / Equity Ratio
3.17-0.342.160.03-0.52-1.27
Upgrade
Net Debt / EBITDA Ratio
-0.610.40-0.70-0.041.800.46
Upgrade
Net Debt / FCF Ratio
-0.560.42-0.73-0.031.420.31
Upgrade
Asset Turnover
0.090.140.090.050.100.05
Upgrade
Inventory Turnover
2.174.444.014.673.872.48
Upgrade
Quick Ratio
0.301.900.361.192.831.18
Upgrade
Current Ratio
0.682.140.521.392.931.29
Upgrade
Return on Equity (ROE)
-154.65%-165.90%-170.80%-67.53%-102.65%-
Upgrade
Return on Assets (ROA)
-42.33%-42.63%-43.01%-26.46%-18.88%-26.46%
Upgrade
Return on Capital Employed (ROCE)
-210.90%-77.90%-177.90%-80.40%-30.90%-55.60%
Upgrade
Earnings Yield
-42.84%-21.50%----
Upgrade
FCF Yield
-39.69%-16.63%----
Upgrade
Buyback Yield / Dilution
-14.60%-13.14%-1.02%-5.71%-364.87%-3.12%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.